-
Hospital admissions related to poor medication adherence cost the United States billions of dollars a year. Two physicians recently reviewed the literature and discussed adherence to medication in the Aug. 5 issue of The New England Journal of Medicine.
-
The FDA has asked Purdue Pharma LP to withdraw its pain management drug hydromorphone hydrochloride (Palladone) from the market. The agency made this request after acquiring new information about serious and potentially fatal adverse reactions that can occur when hydromorphone extended-release capsules are taken together with alcohol.
-
New indication for celecoxib (Celebrex) by Pfizer. The FDA has approved the selective COX-2 inhibitor celecoxib (Celebrex) for a new indication, the relief of the signs and symptoms associated with ankylosing spondylitis.
-
Dexmethylphenidate, d-MPH (Focalin) is a new methylphenidate (d,l-MPH; MPH) formulation of the active enantiomer only. A variety of methylphenidate products are available but only dexmethylphenidate is the purified active enantiomer.
-
-
-
-
FDA Skeptical that Green Tea Reduces Risk of Certain Cancers; NCCAM Offers Continuing Education Series on Complementary and Alternative Medicine; Nationwide Alert Issued for “Liqiang 4” Because of Potential Health Risk. Altern Ther Women's Health 2005;7(9):71-72.
-
-
Milan FB. Treatment of premenstrual syndrome with Vitamin B6. Altern Ther Women's Health 2005;7(9):65-69.
